Hilton Again Named No. 1 World’s Best Workplace
13.11.2025 13:16:00 CET | Business Wire | Press Release
Once again named the No. 1 World’s Best Workplace by Fortune and Great Place to Work,Hilton (NYSE: HLT) today is releasing findings of a newly commissioned study linking the role of employee experience to consumer purchasing decisions and service experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112613594/en/
Courtesy of Hilton
According to a new survey conducted by Morning Consult for Hilton*:
- Nearly 80% of U.S. consumers (78%) say that companies that take good care of their employees provide better products and services, with nearly 90% (88%) saying that taking care of employees is especially important for travel and hospitality brands.
- Three out of every four U.S. consumers (75%) say they are more likely to recommend doing business with a company that is known to treat its employees well.
Hilton’s commitment to providing a strong workplace culture, which for a decade has landed it on the World’s Best Workplace list, is centered on enabling career growth for team members, who are at the heart of providing great service for its guests. According to internal company data, the vast majority of Hilton team members globally say they believe the company is a great place to work (93%) because of its unwavering investment in their long-term growth potential and wellbeing:
- Nine out of every 10 (91%) team members believe they can continue to learn and grow;
- Nearly 90% (87%) of team members believe they can achieve their career goals at Hilton;
- Nearly two-thirds (63%) of recent hotel and corporate leadership roles have been filled by internal candidates, with first-time managers in the U.S. earning their promotions into Hilton management roles, on average, in just four years;
- One third of U.S. team members (32%) have been with Hilton for more than a decade; and
- 85% of U.S. team members say they feel balanced and healthy at work.
“This milestone goes beyond rankings — it’s a reflection of who we are and what we’ve always believed: When we take great care of our people, they take great care of our guests,” said Chris Nassetta, president and chief executive officer, Hilton. “Our 500,000 team members around the world are united by a common purpose that our founder, Conrad Hilton, envisioned over a century ago: To fill the earth with the light and warmth of hospitality. It’s that purpose - and the passion and dedication of our team members — that has made Hilton the best place to work and the best place to stay in the world.”
What Makes Hilton the World’s Best Workplace
Hilton’s fast-paced global expansion continues to drive job creation and career growth opportunities around the world. Having opened nearly three hotels every day for the past year, nearly 20,000 team members have been added to Hilton’s global workforce across its managed and franchised hotels, as well as in corporate roles, since September 2024.
Whether team members are just starting on their journey or looking for the next step in their careers, Hilton is prioritizing opportunities for team members to take their jobs and turn them into lifelong careers.
Since 2022, Hilton has created more than 2.5 million learning and career growth opportunities for Hilton team members and community members worldwide through programs that offer a variety of ways to gain new skills, achieve certifications and learn new languages, including:
- LAUNCH: To build a pipeline of future leaders from the start of their Hilton careers, LAUNCH is an early-career rotational program that offers participants a 24-month journey through on-property roles in cities around the world and rotations across key business areas in Hilton’s global headquarters in the United States.
- Hilton University & LinkedIn Learning: Hilton offers free access to education courses through its Hilton University and LinkedIn Learning platforms, featuring nearly 30,000 courses and job certifications from best-in-class partners in education.
- Guild: Hilton was the first hospitality company to offer access to tuition-free, barrier-free educational opportunities to its eligible U.S. team members through Guild. Beginning on day one of employment, Hilton team members have access to Guild’s platform of educational offerings including programs from English language learning to certificates and bootcamps, as well as a variety of degrees.
- Global Language Learning Program: Hilton offers eligible team members around the world access to a free language learning program, offering a flexible, inclusive and accessible approach to learning a new language through self-study platforms, small group lessons and private one-on-one coaching.
- BetterUp Coaching: Hilton launched Manage™ with BetterUp, a nine-month coaching program for first-time or new people leaders designed to build managerial skills and foster high-performing teams.
- Team Member Mentoring: Through MentorcliQ, a best-in-class global provider of mentoring technology, team members are matched based on development goals, experience and interests while fostering meaningful connections between mentors and mentees.
- People Leader Essentials & General Manager Academy: To support current, new and future people leaders, Hilton launched People Leader Essentials, a self-paced curriculum, available to all team members, offering content on key leadership topics. Additionally, Hilton works to provide innovative leadership development programs designed for our top tier talent, including GM Academy, which develops current and aspiring hotel general managers.
In addition to learning and growth opportunities, Hilton provides its team members comprehensive benefits that support their ability to thrive. More than 90% (93%) of Hilton team members say Hilton provides unique and special benefits, including Go Hilton, Hilton’s team member travel program that provides team members with discounted room rates and travel benefits. Other unique benefits include Hilton’s Thrive Sabbatical and Thrive Reset programs, which provide team members with paid time off and financial support to pursue personal passions, recharge or give back.
“We have always believed that an investment in our people is an investment in our business. As the No. 1 Best Workplace once again, we know that a culture built on growth and opportunity doesn’t just create great careers but also creates great guest experiences,” said Laura Fuentes, Hilton’s chief human resources officer and head of Hilton Supply Management. “By building a culture where team members feel seen, welcomed and a part of something greater than themselves, we’re empowering our team members to deliver exceptional service and drive our business forward.”
Hilton’s ranking as the World’s No. 1 Best Place to Work is a result of positive feedback directly from team members among a workforce spanning 500,000 people across 141 countries and territories. Hilton has been recognized as a Great Place to Work in 67 countries in 2025, with No. 1 rankings in 18 countries, including the United States. For more information on careers at Hilton visit jobs.hilton.com.
Great Place to Work Methodology
To determine the World’s Best Workplaces each year, Great Place to Work invites companies to take part in a rigorous, data-based model that quantifies the employee experience. The process includes soliciting employee feedback through surveys, collecting data about company culture and workforces and achieving certification status. From there, companies must be identified as outstanding global employers by appearing on at least five Best Workplaces™ Lists in Asia, Europe, Latin America, Africa, North America, or Australia during 2024 or early 2025. Read more about Great Place to Work’s Methodology here.
*Morning Consult Poll Methodology
Morning Consult conducted two polls on behalf of Hilton exploring consumer attitudes toward how companies care for their employees. The first survey was fielded between Oct. 27-29 among a sample of 2,043 US adults, and the second was fielded between Nov. 1-3, 2025, among a sample of 2,200 US adults. The interviews were conducted online, and the data were weighted to approximate a target sample of adults based on gender, age, race, educational attainment, and region. Results from each survey have a margin of error of +/- 2%. The surveys were conducted in English.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112613594/en/
Contacts
HiltonPR@Hilton.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom